1. Dadzie TG, Green AC. The role of the bone microenvironment in regulating myeloma residual disease and treatment. Front Oncol. 2022; 12:999939. DOI: 10.3389/fonc.2022.999939 [
DOI:10.3389/fonc.2022.999939] [
PMID] [
]
2. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025; 75(1): 10-45. DOI: 10.3322/caac.21871 [
DOI:10.3322/caac.21871] [
PMID] [
]
3. Nahvijou A. Disability-Adjusted Life Years (DALY) for Cancers in Iran, 1990 to 2016: Review of Findings from the Global Burden of Disease Study. Iran J Public Health. 2021; 50(10):2095-104. DOI: 10.18502/ijph.v50i10.7511 [
DOI:10.18502/ijph.v50i10.7511] [
PMID] [
]
4. Michels TC, Petersen KE. Multiple Myeloma: Diagnosis and Treatment. Am Fam Physician. 2017; 95(6): 373-83. URL: https://pubmed.ncbi.nlm.nih.gov/28318212/
5. Egwu CO, Aloke C, Onwe KT, Umoke CI, Nwafor J, Eyo RA, et al. Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine. Molecules. 2024; 29(11): 2584. DOI: 10.3390/molecules29112584 [
DOI:10.3390/molecules29112584] [
PMID] [
]
6. Alvarez-Berríos MP, Sosa-Cintron N, Rodriguez-Lugo M, Juneja R, Vivero-Escoto JL. Hybrid Nanomaterials Based on Iron Oxide Nanoparticles and Mesoporous Silica Nanoparticles: Overcoming Challenges in Current Cancer Treatments. J Chem. 2016; 2016: 2672740. DOI: [
DOI:10.1155/2016/2672740]
7. Hesari A, Azizian M, Sheikhi A, Nesaei A, Sanaei S, Mahinparvar N, et al. Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status. Int J Cancer. 2019; 144(6): 1215-26. DOI: 10.1002/ijc.31947 [
DOI:10.1002/ijc.31947] [
PMID]
8. Ghasemi F, Shafiee M, Banikazemi Z, Pourhanifeh MH, Khanbabaei H, Shamshirian A, et al. Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells. Pathol Res Pract. 2019; 215(10): 152556. DOI: 10.1016/j.prp.2019.152556 [
DOI:10.1016/j.prp.2019.152556] [
PMID]
9. Allegra A, Speciale A, Molonia MS, Guglielmo L, Musolino C, Ferlazzo G, et al. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways. Toxicol In Vitro. 2018; 47: 186-94. DOI: 10.1016/j.tiv.2017.12.001 [
DOI:10.1016/j.tiv.2017.12.001] [
PMID]
10. Sharifi S, Dalir Abdolahinia E, Ghavimi MA, Dizaj SM, Aschner M, Saso L, et al. Effect of Curcumin-Loaded Mesoporous Silica Nanoparticles on the Head and Neck Cancer Cell Line, HN5. Curr Issues Mol Biol. 2022; 44(11): 5247-59. DOI: 10.3390/cimb44110357 [
DOI:10.3390/cimb44110357] [
PMID] [
]
11. Mirzaei H, Bagheri H, Ghasemi F, Khoi JM, Pourhanifeh MH, Heyden YV, et al. Anti-Cancer Activity of Curcumin on Multiple Myeloma. Anticancer Agents Med Chem. 2021; 21(5): 575-86. DOI: 10.2174/1871520620666200918113625 [
DOI:10.2174/1871520620666200918113625] [
PMID]
12. Pedraza D, Díez J, Isabel-Izquierdo-Barba, Colilla M, Vallet-Regí M. Amine-Functionalized Mesoporous Silica Nanoparticles: A New Nanoantibiotic for Bone Infection Treatment. Biomedical Glasses. 2018; 4(1): 1-12. DOI: 10.1515/bglass-2018-0001 [
DOI:10.1515/bglass-2018-0001]
13. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006; 1(3): 1458-61. DOI: 10.1038/nprot.2006.238 [
DOI:10.1038/nprot.2006.238] [
PMID]
14. Lv Y, Li J, Chen H, Bai Y, Zhang L. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier. Int J Nanomedicine. 2017; 12: 4361-70. DOI: 10.2147/IJN.S135626 [
DOI:10.2147/IJN.S135626] [
PMID] [
]
15. Chng WJ, Bergsagel PL. The molecular biology of multiple myeloma. Molecular Hematology. London: Wiley-Blackwell; 2019. p. 121-30. DOI: [
DOI:10.1002/9781119252863.ch10]
16. Yang G, Liu Y, Wang H, Wilson R, Hui Y, Yu L, et al. Bioinspired Core-Shell Nanoparticles for Hydrophobic Drug Delivery. Angew Chem Int Ed Engl. 2019; 58(40): 14357-64. DOI: 10.1002/anie.201908357 [
DOI:10.1002/anie.201908357] [
PMID]
17. Hu T, Yang J, Cui K, Rao Q, Yin T, Tan L, et al. Controlled Slow-Release Drug-Eluting Stents for the Prevention of Coronary Restenosis: Recent Progress and Future Prospects. ACS Appl Mater Interfaces. 2015; 7(22): 11695-712. DOI: 10.1021/acsami.5b01993 [
DOI:10.1021/acsami.5b01993] [
PMID]
18. Liu C, Jiang F, Xing Z, Fan L, Li Y, Wang S, et al. Efficient Delivery of Curcumin by Alginate Oligosaccharide Coated Aminated Mesoporous Silica Nanoparticles and In Vitro Anticancer Activity against Colon Cancer Cells. Pharmaceutics. 2022; 14(6): 1166. DOI: 10.3390/pharmaceutics14061166 [
DOI:10.3390/pharmaceutics14061166] [
PMID] [
]
19. Mohebian Z, Babazadeh M, Zarghami N. In Vitro Efficacy of Curcumin-Loaded Amine-Functionalized Mesoporous Silica Nanoparticles against MCF-7 Breast Cancer Cells. Adv Pharm Bull. 2023; 13(2): 317-27. DOI: 10.34172/apb.2023.035 [
DOI:10.34172/apb.2023.035] [
PMID] [
]
20. Bai Q, Liu Q. Antitumor Effects and Mechanisms of Curcumin On Human Multiple Myeloma Cell Lines. Blood. 2009; 114(22): 4896. DOI: [
DOI:10.1182/blood.V114.22.4896.4896]
21. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, Aggarwal BB. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther. 2009; 8(4): 959-70. DOI: 10.1158/1535-7163.MCT-08-0905 [
DOI:10.1158/1535-7163.MCT-08-0905] [
PMID] [
]
22. Zhang XY, Bai QX, Huang GS, Zhao H, Chen JJ, Yang LJ. [Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011; 19(3): 684-8. [Article in Chinese] URL: https://pubmed.ncbi.nlm.nih.gov/21729550/